BSEGodavari Drugs LtdMediumPositive
Announced Fri, 20 Mar · 18:26 IST

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tanushree Kakani

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+7.8%1-day move
₹82.50
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+7.8+9.1+3.7+4.2+13.9+10.3+50.3+44.5+53.9+47.9
Up moveDown movePending
AI summary

Tanushree Kakani, a promoter of Godavari Drugs Ltd, has disclosed the acquisition of 1,38,000 convertible warrants through a preferential issue on 18 March 2026. Before the acquisition, she held 1,40,000 shares (1.86% of voting capital). After the allotment, her total holding rises to 2,78,000 instruments — 1,40,000 shares plus 1,38,000 warrants — representing 1.38% of current share capital and 2.23% of fully diluted share capital. The company's total share capital expanded from 75.30 lakh to 1.01 crore equity shares (Rs.10 face value) as a result of this preferential issue. The filing is made under Regulation 29(2) of SEBI's Takeover Regulations, 2011.

Likely market impact

This signals promoter confidence in the company through fresh capital infusion via preferential allotment, though the individual holding remains small at under 3% on a diluted basis. The expansion of the company's equity base by roughly 34% may lead to share dilution for existing non-promoter shareholders over time.